Today's News |
Vesalius Cardiovascular Awarded Top Prize and $300,000 at 2019 Innovators' Challenge by VGH and UBC Hospital Foundation
Tuesday, June 25, 2019
Vancouver, BC, June 25, 2019--(T-Net)--Vesalius Cardiovascular has taken home the 2019 Innovators' Challenge presented by the VGH and UBC Hospital Foundation, winning the top prize of $300,000.
Led by Dr. Peter Skarsgard, Vesalius Cardiovascular has made tremendous advancements in mitral regurgitation technology through their implanted medical device that is delivered to the heart percutaneously (through a vein in the leg).
Based on proven surgical concepts, their device drastically reduces patient recovery time from 2 to 3 months, to 2 to 3 days, allowing patients to return to their normal routine and activities while also reducing costs for the medical system.
Mitral regurgitation (MR) is the most common heart valve disease affecting 5% of Western populations. Of this group, 20% require treatment which, before now, was open heart surgery. Due to the associated risks, many patients were ineligible for surgery and as such were left with their needs unmet.
Vesalius Cardiovascular helps to avoid these risks and offers an option to patients through their device providing the benefit of surgery without the risk of surgery.
Read more about Vesalius Cardiovascular here.
About Vesalius Cardiovascular
Vesalius Cardiovascular is a Canadian medical device venture founded in 2016 in Vancouver, British Columbia. The company specializes in designing, developing and commercializing biomedical devices for the treatment of cardiovascular disease, specifically mitral valve regurgitation (MR).
Our devices will be introduced percutaneously to the heart, eliminating the need for open heart surgery and the related risks. The procedure can be performed by a Cardiovascular Interventionalist (Cardiologist or Cardiac Surgeon).
Vesalius Cardiovascular is the result of several years of intensive private research and investigation. The inventor behind Vesalius Cardiovascular is Dr. Peter Skarsgard, a Vancouver-based Cardiac Surgeon, and Head of the Division of Cardiovascular Surgery at Vancouver General Hospital.
The venture will be managed as a lean Research and Development Initiative, with a scientific feedback and inputs from our Board of some of BC's most prominent clinicians.
Vesalius Cardiovascular is currently developing Calla, a biomedical device that can be introduced percutaneously to the heart, for the treatment of degenerative MR (due to mitral valve prolapse), the most common variety of MR. The principles of surgical mitral valve repair are utilized, but sternotomy, heart-lung bypass, and cardiac arrest - components of an open heart operation - are not required.
News Source: Entrepreneurship at UBC (https://www.start.entrepreneurship.ubc.ca)
Other Recent Company News |
||||||||||
|